Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GDHG: 0.092
52 Week Range 0.0828 - 24.9900
Shares Outstanding 186.55M
Float 38.59M
FORM 13 ( Friday 08/05) shows that the Company Director's ownership stake has increased from 19.3% to 71% https://t.co/6EUqAIRmbj pic.twitter.com/LNjGiFZsAp
On August 2, 2024, Golden Heaven Group Holdings Ltd. (the “Company”) entered into a share purchase agreement (the “Agreement”) with an investor (the“Investor”). Pursuant to the Agreement, the Investor agreed to purchase, and the Company agreed to issue and sell to the Investor, (i) 15,000,000 Class A ordinary shares of the Company, par value of $0.0001 per share (the “Shares”), at a purchase price of $0.15 per share, and (ii) a warrant to purchase up to 30,000,000 Class A ordinary shares of the Company at an exercise price of US$0.20 per share (the “Warrant”), for an aggregate purchase price of $2,250,000
The closing of the transactions contemplated by the Agreement took place on August 8, 2024. The Company received gross proceeds of approximately
$2,250,000 from the issuance and sale of the Shares and Warrant and intends to use the net proceeds from the Offering for working capital and other general corporate purposes
On July 26, 2024, the Company closed the Private Placement and issued the Warrants and an aggregate of 120,000,000 Class A Ordinary Shares to the Investors at a price of $0.15 per share, for aggregate gross proceeds of approximately $18 million, before deducting the offering expenses payable by the Company. The Company intends to use the net proceeds from the Private Placement for working capital and other general corporate purposes.
Time for a strong rebound:
Aug 15, 2024 0.1000 0.1045 0.0828 0.0880 0.0880 2,505,665
Aug 14, 2024 0.1150 0.1170 0.1060 0.1090 0.1090 3,115,500
Aug 13, 2024 0.1190 0.1220 0.1140 0.1190 0.1190 1,411,000
Aug 12, 2024 0.1150 0.1230 0.1130 0.1190 0.1190 1,881,300
Aug 09, 2024 0.1230 0.1240 0.1120 0.1170 0.1170 3,065,600
Aug 08, 2024 0.1220 0.1250 0.1150 0.1220 0.1220 2,473,300
Aug 07, 2024 0.1230 0.1300 0.1210 0.1240 0.1240 1,949,600
Aug 06, 2024 0.1370 0.1390 0.1020 0.1270 0.1270 6,068,100
Aug 05, 2024 0.1650 0.1670 0.1210 0.1430 0.1430 29,959,700
https://ir.jsyoule.com/
ASTC: 8.9
News coming?? very high volume
Aug 15, 2024 8.85 8.90 8.83 8.83 8.83 4,455
Aug 14, 2024 9.70 10.00 8.75 8.89 8.89 71,400
Aug 13, 2024 8.70 9.03 8.30 9.03 9.03 78,200
Aug 12, 2024 8.24 9.00 8.24 9.00 9.00 66,600
Aug 09, 2024 8.29 8.30 8.20 8.25 8.25 2,200
Aug 08, 2024 8.15 8.19 8.15 8.19 8.19 1,800
Aug 07, 2024 8.16 8.16 8.16 8.16 8.16 400
Aug 06, 2024 8.01 8.39 8.01 8.16 8.16 5,600
Aug 05, 2024 7.94 8.12 7.94 8.07 8.07 1,500
Aug 02, 2024 8.07 8.25 8.07 8.21 8.21 2,500
Aug 01, 2024 8.25 8.30 8.25 8.30 8.30 900
ASTC: 8.9
News coming?? very high volume
Aug 15, 2024 8.85 8.90 8.83 8.83 8.83 4,455
Aug 14, 2024 9.70 10.00 8.75 8.89 8.89 71,400
Aug 13, 2024 8.70 9.03 8.30 9.03 9.03 78,200
Aug 12, 2024 8.24 9.00 8.24 9.00 9.00 66,600
Aug 09, 2024 8.29 8.30 8.20 8.25 8.25 2,200
Aug 08, 2024 8.15 8.19 8.15 8.19 8.19 1,800
Aug 07, 2024 8.16 8.16 8.16 8.16 8.16 400
Aug 06, 2024 8.01 8.39 8.01 8.16 8.16 5,600
Aug 05, 2024 7.94 8.12 7.94 8.07 8.07 1,500
Aug 02, 2024 8.07 8.25 8.07 8.21 8.21 2,500
Aug 01, 2024 8.25 8.30 8.25 8.30 8.30 900
Theravet (BE0974387194) Euronext Growth Paris et Bruxelles : 0.225
52w: 0.216 – 2.4
https://www.thera.vet/en/home
https://www.theravet-finances.com/images/202404_Theravet_Company_Presentation_Competition_Sport_Horses.pdf
their products:
https://bioceravet.com/en/shop-bone-surgery/
https://bioceravet.com/en/shop-osteosarcoma/
https://bioceravet.com/en/shop-equine/
A company with a lot of potential, 0 new shares since IPO but mkt cap from 31 million to 0.7 million euro.
Have reduced the workforce by 1/3 to keep more cash in the company
Admitted shares 3,223,936
Enrico Bastianelli (CEO) 20,43 %
Other shareholders 5,93 %
Free float 22,78 %
Innovation Fund 14,09 %
Investsud 11,34 %
Luxembourg Développement Europe 2 11,34 %
Theodorus III 14,09 %
Source: Cofisem - Last Update: 18 Feb 2024
level2
0,224 1.000 1
0,225 500 1
0,226 1.500 1
0,239 553 1
0,24 2.500 1
0,25 6.114 1
0,269 2.500 1
0,3 543 3
0,319 4.500 2
0,32 1.000 1
Theravet (BE0974387194) Euronext Growth Paris et Bruxelles : 0.225
52w: 0.216 – 2.4
https://www.thera.vet/en/home
https://www.theravet-finances.com/images/202404_Theravet_Company_Presentation_Competition_Sport_Horses.pdf
their products:
https://bioceravet.com/en/shop-bone-surgery/
https://bioceravet.com/en/shop-osteosarcoma/
https://bioceravet.com/en/shop-equine/
A company with a lot of potential, 0 new shares since IPO but mkt cap from 31 million to 0.7 million euro.
Have reduced the workforce by 1/3 to keep more cash in the company
Admitted shares 3,223,936
Enrico Bastianelli (CEO) 20,43 %
Other shareholders 5,93 %
Free float 22,78 %
Innovation Fund 14,09 %
Investsud 11,34 %
Luxembourg Développement Europe 2 11,34 %
Theodorus III 14,09 %
Source: Cofisem - Last Update: 18 Feb 2024
level2
0,224 1.000 1
0,225 500 1
0,226 1.500 1
0,239 553 1
0,24 2.500 1
0,25 6.114 1
0,269 2.500 1
0,3 543 3
0,319 4.500 2
0,32 1.000 1
MULN: 0.5975 🤔
52 Week Range 0.59 - 108.0000
Book Value Per Share (mrq) 7.68
Short % of shares 24.43%
Time for a strong recovery
Today: 24,859,163 shares x 0.5975 = 14.8 M
07/05/2024 16,031,470 shares x 2.42 = 38.8 M
As of May 9, 2024, a total of 11,412,596 shares x 7.65 = 87.3 M
https://www.mullenusa.com/manufacturing
Company total assets are expected to be approximately $191.4 million as of June 30, 2024, and will be reported in the Company’s quarterly report to be filed on or about Aug. 12, 2024
Company cash on hand exceeds current market capitalization
Mullen has achieved all federal and state regulatory requirements for Class 1 and Class 3 commercial vehicles and is actively manufacturing and selling Class 1 and Class 3 commercial vehicles across the U.S.
BREA, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- via IBN -- Mullen Automotive Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), a US-based manufacturer of commercial electric vehicles (“EV”), today shares an update from CEO and chairman David Michery, providing status on various matters and Company initiatives.
Dear Mullen Shareholders,
Despite challenging economic headwinds where many enterprises are capital-constrained, our balance sheet remains strong, and we have achieved meaningful accomplishments since our last update to shareholders in June 2024.
With Company total assets expected to be approximately $191.4 million as of June 30, 2024, and a cash position that surpasses our current market capitalization, we believe that Mullen has a strong financial foundation for future growth in our electric vehicle sales.
• Our team of experienced automotive veterans has successfully navigated the complex regulatory landscape achieving all federal and state regulatory requirements and qualifying for multiple state level incentives that will help make our EVs more affordable, promoting additional sales. Mullen is actively manufacturing and selling both Class 1 and Class 3 commercial electric vehicles across the United States, demonstrating our commitment to bring clean transportation solutions to market. Additionally, our B4 Class 4 electric truck, offered through our Bollinger Motors subsidiary, has achieved EPA certification, a major step forward as manufacturing begins in the second half of 2024.
As of Aug. 6, 2024, we are proud to highlight the following accomplishments:
Securing Financial Resources for Growth
• As recently announced, we have secured $250 million in new financing commitments, providing us with the financial resources to accelerate our growth plan. Of the $250 million in financing, $50 million has been received, $50 million is a one-year additional investment right where the investors have the right, but not the obligation, to provide additional financing, and $150 million is pursuant to an equity line of credit as described in the Company’s Form 8-K, filed with the Securities and Exchange Commission on May 24, 2024.
Expanding Our Sales and Distribution Reach
• Mullen expanded its distribution network to six dealerships and has added five new commercial dealer partners during the quarter.
• Bollinger Motors, our electric truck subsidiary, has announced four commercial dealers throughout the U.S.
• The Company is actively engaged in adding more dealer partners and further expanding our retail distribution network across the U.S. and internationally.
Winning New Customers and Delivering Vehicles
• Bollinger Motors has reached agreements to sell over 200 B4 commercial Class 4 EV trucks to-date.
• The Company recently expanded its international distribution with orders received from our authorized dealer, GAMA, based in southeastern Europe, for commercial EVs, including the Mullen GO, a micro urban delivery vehicle, and Class 1 and 3 EV cargo vans and trucks.
• Mullen is actively engaged in negotiations with major telecoms, large fleet providers, delivery companies, universities, local municipalities, government agencies, and airport service providers to expand our customer base and market share.
Importantly, the Company’s Tunica, Mississippi, commercial vehicle center has manufactured hundreds of our Class 1 and Class 3 electric vehicles in 2024 and we’ve begun to fulfil our previously announced orders from our facilities proudly based in the United States.
Developing Technologies for Future Growth
• The Company is advancing its solid-state polymer pack program and is continuing to conduct battery and vehicle testing since Class 1 EV cargo van road testing began in February 2024.
• Recently, the Company has identified lead suppliers for development and components and issued initial purchase orders to support this pivotal program.
• The Company expects to have the solid-state polymer packs fully certified for production and sale in the second half of 2025.
These achievements are a testament to the hard work and dedication of our team, and we are excited about the opportunities ahead. We remain focused on delivering value to our shareholders through innovation, operational excellence and strategic partnerships.
Thank you for your continued support.
Sincerely,
David Michery
CEO and chairman
About Mullen
Mullen Automotive (NASDAQ: MULN) is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. Recently, CARB issued HVIP approval on the Mullen THREE, Class 3 EV truck, providing up to a $45,000 cash voucher at time of vehicle purchase. The Company has also recently expanded its commercial dealer network with the addition of Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group and Eco Auto, providing sales and service coverage in key Midwest, West Coast and Pacific Northwest and New England markets. The Company also recently announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles.
To learn more about the Company, visit www.MullenUSA.com.
MULN: 0.5975 🤔
52 Week Range 0.59 - 108.0000
Book Value Per Share (mrq) 7.68
Short % of shares 24.43%
Time for a strong recovery
Today: 24,859,163 shares x 0.5975 = 14.8 M
07/05/2024 16,031,470 shares x 2.42 = 38.8 M
As of May 9, 2024, a total of 11,412,596 shares x 7.65 = 87.3 M
https://www.mullenusa.com/manufacturing
Company total assets are expected to be approximately $191.4 million as of June 30, 2024, and will be reported in the Company’s quarterly report to be filed on or about Aug. 12, 2024
Company cash on hand exceeds current market capitalization
Mullen has achieved all federal and state regulatory requirements for Class 1 and Class 3 commercial vehicles and is actively manufacturing and selling Class 1 and Class 3 commercial vehicles across the U.S.
BREA, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- via IBN -- Mullen Automotive Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), a US-based manufacturer of commercial electric vehicles (“EV”), today shares an update from CEO and chairman David Michery, providing status on various matters and Company initiatives.
Dear Mullen Shareholders,
Despite challenging economic headwinds where many enterprises are capital-constrained, our balance sheet remains strong, and we have achieved meaningful accomplishments since our last update to shareholders in June 2024.
With Company total assets expected to be approximately $191.4 million as of June 30, 2024, and a cash position that surpasses our current market capitalization, we believe that Mullen has a strong financial foundation for future growth in our electric vehicle sales.
• Our team of experienced automotive veterans has successfully navigated the complex regulatory landscape achieving all federal and state regulatory requirements and qualifying for multiple state level incentives that will help make our EVs more affordable, promoting additional sales. Mullen is actively manufacturing and selling both Class 1 and Class 3 commercial electric vehicles across the United States, demonstrating our commitment to bring clean transportation solutions to market. Additionally, our B4 Class 4 electric truck, offered through our Bollinger Motors subsidiary, has achieved EPA certification, a major step forward as manufacturing begins in the second half of 2024.
As of Aug. 6, 2024, we are proud to highlight the following accomplishments:
Securing Financial Resources for Growth
• As recently announced, we have secured $250 million in new financing commitments, providing us with the financial resources to accelerate our growth plan. Of the $250 million in financing, $50 million has been received, $50 million is a one-year additional investment right where the investors have the right, but not the obligation, to provide additional financing, and $150 million is pursuant to an equity line of credit as described in the Company’s Form 8-K, filed with the Securities and Exchange Commission on May 24, 2024.
Expanding Our Sales and Distribution Reach
• Mullen expanded its distribution network to six dealerships and has added five new commercial dealer partners during the quarter.
• Bollinger Motors, our electric truck subsidiary, has announced four commercial dealers throughout the U.S.
• The Company is actively engaged in adding more dealer partners and further expanding our retail distribution network across the U.S. and internationally.
Winning New Customers and Delivering Vehicles
• Bollinger Motors has reached agreements to sell over 200 B4 commercial Class 4 EV trucks to-date.
• The Company recently expanded its international distribution with orders received from our authorized dealer, GAMA, based in southeastern Europe, for commercial EVs, including the Mullen GO, a micro urban delivery vehicle, and Class 1 and 3 EV cargo vans and trucks.
• Mullen is actively engaged in negotiations with major telecoms, large fleet providers, delivery companies, universities, local municipalities, government agencies, and airport service providers to expand our customer base and market share.
Importantly, the Company’s Tunica, Mississippi, commercial vehicle center has manufactured hundreds of our Class 1 and Class 3 electric vehicles in 2024 and we’ve begun to fulfil our previously announced orders from our facilities proudly based in the United States.
Developing Technologies for Future Growth
• The Company is advancing its solid-state polymer pack program and is continuing to conduct battery and vehicle testing since Class 1 EV cargo van road testing began in February 2024.
• Recently, the Company has identified lead suppliers for development and components and issued initial purchase orders to support this pivotal program.
• The Company expects to have the solid-state polymer packs fully certified for production and sale in the second half of 2025.
These achievements are a testament to the hard work and dedication of our team, and we are excited about the opportunities ahead. We remain focused on delivering value to our shareholders through innovation, operational excellence and strategic partnerships.
Thank you for your continued support.
Sincerely,
David Michery
CEO and chairman
About Mullen
Mullen Automotive (NASDAQ: MULN) is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. Recently, CARB issued HVIP approval on the Mullen THREE, Class 3 EV truck, providing up to a $45,000 cash voucher at time of vehicle purchase. The Company has also recently expanded its commercial dealer network with the addition of Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group and Eco Auto, providing sales and service coverage in key Midwest, West Coast and Pacific Northwest and New England markets. The Company also recently announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles.
To learn more about the Company, visit www.MullenUSA.com.
Theravet (BE0974387194) Euronext Growth Paris et Bruxelles : 0.22
52w: 0.22 – 2.4
https://www.thera.vet/en/home
https://www.theravet-finances.com/images/202404_Theravet_Company_Presentation_Competition_Sport_Horses.pdf
their products:
https://bioceravet.com/en/shop-bone-surgery/
https://bioceravet.com/en/shop-osteosarcoma/
https://bioceravet.com/en/shop-equine/
A company with a lot of potential, 0 new shares since IPO but mkt cap from 31 million to 0.7 million euro.
Have reduced the workforce by 1/3 to keep more cash in the company
Admitted shares 3,223,936
Enrico Bastianelli (CEO) 20,43 %
Other shareholders 5,93 %
Free float 22,78 %
Innovation Fund 14,09 %
Investsud 11,34 %
Luxembourg Développement Europe 2 11,34 %
Theodorus III 14,09 %
Source: Cofisem - Last Update: 18 Feb 2024
level2
0,248 1.000 1
0,255 1.002 1
0,3 463 1
0,352 1.600 1
0,4 160 2
0,48 1.990 1
0,498 40.000 1
0,61 189 1
0,68 200 1
0,696 200 1
Theravet (BE0974387194) Euronext Growth Paris et Bruxelles : 0.22
52w: 0.22 – 2.4
https://www.thera.vet/en/home
https://www.theravet-finances.com/images/202404_Theravet_Company_Presentation_Competition_Sport_Horses.pdf
their products:
https://bioceravet.com/en/shop-bone-surgery/
https://bioceravet.com/en/shop-osteosarcoma/
https://bioceravet.com/en/shop-equine/
A company with a lot of potential, 0 new shares since IPO but mkt cap from 31 million to 0.7 million euro.
Have reduced the workforce by 1/3 to keep more cash in the company
Admitted shares 3,223,936
Enrico Bastianelli (CEO) 20,43 %
Other shareholders 5,93 %
Free float 22,78 %
Innovation Fund 14,09 %
Investsud 11,34 %
Luxembourg Développement Europe 2 11,34 %
Theodorus III 14,09 %
Source: Cofisem - Last Update: 18 Feb 2024
level2
0,248 1.000 1
0,255 1.002 1
0,3 463 1
0,352 1.600 1
0,4 160 2
0,48 1.990 1
0,498 40.000 1
0,61 189 1
0,68 200 1
0,696 200 1
All time low
Taoping Inc. (TAOP) 0.52
52 Week Range 0.52 - 5.3300
Shares Outstanding 4.52M
Float 2.54M
Book Value Per Share (mrq) 4.41
http://en.taop.com/news.html
Taoping Inc. (Nasdaq: TAOP) has a long history of successfully leveraging technology in the development of innovative solutions to help customers in both the private and public sectors to more effectively communicate and market to their desired targets. The Company has built a far-reaching city partner ecosystem and comprehensive portfolio of high-value, high-traffic areas for its products, which are aligned together with Taoping's smart cloud platform, cloud services and solutions, new media and artificial intelligence. For more information about Taoping, please visit www.taop.com. You can also follow us on X.
All time low
Taoping Inc. (TAOP) 0.52
52 Week Range 0.52 - 5.3300
Shares Outstanding 4.52M
Float 2.54M
Book Value Per Share (mrq) 4.41
http://en.taop.com/news.html
Taoping Inc. (Nasdaq: TAOP) has a long history of successfully leveraging technology in the development of innovative solutions to help customers in both the private and public sectors to more effectively communicate and market to their desired targets. The Company has built a far-reaching city partner ecosystem and comprehensive portfolio of high-value, high-traffic areas for its products, which are aligned together with Taoping's smart cloud platform, cloud services and solutions, new media and artificial intelligence. For more information about Taoping, please visit www.taop.com. You can also follow us on X.
Taoping Inc. (TAOP) 0.5919-0.0621 (-9.50%)
52 Week Range 0.5701 - 5.3300
Shares Outstanding 4.52M
Float 2.54M
Book Value Per Share (mrq) 4.41
http://en.taop.com/news.html
Taoping Inc. (Nasdaq: TAOP) has a long history of successfully leveraging technology in the development of innovative solutions to help customers in both the private and public sectors to more effectively communicate and market to their desired targets. The Company has built a far-reaching city partner ecosystem and comprehensive portfolio of high-value, high-traffic areas for its products, which are aligned together with Taoping's smart cloud platform, cloud services and solutions, new media and artificial intelligence. For more information about Taoping, please visit www.taop.com. You can also follow us on X.
Taoping Inc. (TAOP) 0.5919-0.0621 (-9.50%)
52 Week Range 0.5701 - 5.3300
Shares Outstanding 4.52M
Float 2.54M
Book Value Per Share (mrq) 4.41
http://en.taop.com/news.html
Taoping Inc. (Nasdaq: TAOP) has a long history of successfully leveraging technology in the development of innovative solutions to help customers in both the private and public sectors to more effectively communicate and market to their desired targets. The Company has built a far-reaching city partner ecosystem and comprehensive portfolio of high-value, high-traffic areas for its products, which are aligned together with Taoping's smart cloud platform, cloud services and solutions, new media and artificial intelligence. For more information about Taoping, please visit www.taop.com. You can also follow us on X.
RCON: 2.14 + 44.81%
Less than 8 million shares
Float 4.89M
Time for a strong recovery:
Total Cash (mrq) 35.74M
Total Cash Per Share (mrq) 3.77
Total Debt (mrq) 4.67M
Book Value Per Share (mrq) 6.28
RCON: 2.14 + 44.81%
Less than 8 million shares
Float 4.89M
Time for a strong recovery:
Total Cash (mrq) 35.74M
Total Cash Per Share (mrq) 3.77
Total Debt (mrq) 4.67M
Book Value Per Share (mrq) 6.28
GDHG: premarket: $0.1973 +0.0628 +46.69%
Very huge volume!!
52 Week Range 0.1200 - 24.9900
$GDHG $0.1590+17% new highs 🧐
— TheBull (@TheBull_Stocks) August 5, 2024
FORM 13 (Late Friday) shows that the Company Director's ownership stake has increased from 19.3% to 71% https://t.co/6EUqAIRmbj pic.twitter.com/LNjGiFZsAp
GDHG: premarket: $0.1973 +0.0628 +46.69%
Very huge volume!!
52 Week Range 0.1200 - 24.9900
$GDHG $0.1590+17% new highs 🧐
— TheBull (@TheBull_Stocks) August 5, 2024
FORM 13 (Late Friday) shows that the Company Director's ownership stake has increased from 19.3% to 71% https://t.co/6EUqAIRmbj pic.twitter.com/LNjGiFZsAp
Great news at GDHG : 0.1345
After⏲Hours$GDHG - Golden Heaven Group Holdings Ltd.
🔹Files SG 13/ New Owner
🔹Cuizhang Gong Acquires 71% of the company pic.twitter.com/0KqQX6ZNHw
— John Zidar (@JohnZidar) August 2, 2024
After-Hours $0.2187 + 0.0842 (62.61%)
Trading 10x under BV $gdhg. Huge institutional news today too pic.twitter.com/QBUwMJQkkM
— No1bettertrader$$$ (@no1bettertrader) August 2, 2024
$MWG Don’t get left behind🚀
60 Mil in assets
Profitble company
Recent Contract $18M
Price 15mcap🔥$gdhg $rr $shim $sgmo $ante $edbl $tvgn $vbiv $cdio $mgol $cnsp $vsee $op $hubc $spcb $rdhl $xcur $maxn $btc $nuze $serv $pmec $ifbd $mlgo $holo $amc $gme $chwy $djt $idai pic.twitter.com/DtWULBNzWf
— Paraboljoker (@Jokerparabol) August 2, 2024
Great news at GDHG : 0.1345
After⏲Hours$GDHG - Golden Heaven Group Holdings Ltd.
— John Zidar (@JohnZidar) August 2, 2024
🔹Files SG 13/ New Owner
🔹Cuizhang Gong Acquires 71% of the company pic.twitter.com/0KqQX6ZNHw
Trading 10x under BV $gdhg. Huge institutional news today too pic.twitter.com/QBUwMJQkkM
— No1bettertrader$$$ (@no1bettertrader) August 2, 2024
$MWG Don’t get left behind🚀
— Paraboljoker (@Jokerparabol) August 2, 2024
60 Mil in assets
Profitble company
Recent Contract $18M
Price 15mcap🔥$gdhg $rr $shim $sgmo $ante $edbl $tvgn $vbiv $cdio $mgol $cnsp $vsee $op $hubc $spcb $rdhl $xcur $maxn $btc $nuze $serv $pmec $ifbd $mlgo $holo $amc $gme $chwy $djt $idai pic.twitter.com/DtWULBNzWf
Great news at GDHG : 0.1345
After⏲Hours$GDHG - Golden Heaven Group Holdings Ltd.
— John Zidar (@JohnZidar) August 2, 2024
🔹Files SG 13/ New Owner
🔹Cuizhang Gong Acquires 71% of the company pic.twitter.com/0KqQX6ZNHw
Trading 10x under BV $gdhg. Huge institutional news today too pic.twitter.com/QBUwMJQkkM
— No1bettertrader$$$ (@no1bettertrader) August 2, 2024
$MWG Don’t get left behind🚀
— Paraboljoker (@Jokerparabol) August 2, 2024
60 Mil in assets
Profitble company
Recent Contract $18M
Price 15mcap🔥$gdhg $rr $shim $sgmo $ante $edbl $tvgn $vbiv $cdio $mgol $cnsp $vsee $op $hubc $spcb $rdhl $xcur $maxn $btc $nuze $serv $pmec $ifbd $mlgo $holo $amc $gme $chwy $djt $idai pic.twitter.com/DtWULBNzWf
MULN: 0.88
52 Week Range 0.8752 - 117.0000
Book Value Per Share (mrq) 7.68
Short % of shares 24.43%
Time for a strong recovery
Today: 24,859,163 shares x 0.88 = 21.8 M
07/05/2024 16,031,470 shares x 2.42 = 38.8 M
As of May 9, 2024, a total of 11,412,596 shares x 7.65 = 87.3 M
https://www.mullenusa.com/manufacturing
MULN: 0.88
52 Week Range 0.8752 - 117.0000
Book Value Per Share (mrq) 7.68
Short % of shares 24.43%
Time for a strong recovery
Today: 24,859,163 shares x 0.88 = 21.8 M
07/05/2024 16,031,470 shares x 2.42 = 38.8 M
As of May 9, 2024, a total of 11,412,596 shares x 7.65 = 87.3 M
https://www.mullenusa.com/manufacturing
Theravet (BE0974387194) Euronext Growth Paris et Bruxelles : 0.234
52w: 0.234 – 2.4
https://www.thera.vet/en/home
https://www.theravet-finances.com/images/202404_Theravet_Company_Presentation_Competition_Sport_Horses.pdf
their products:
https://bioceravet.com/en/shop-bone-surgery/
https://bioceravet.com/en/shop-osteosarcoma/
https://bioceravet.com/en/shop-equine/
A company with a lot of potential, 0 new shares since IPO but mkt cap from 31 million to 0.7 million euro.
Have reduced the workforce by 1/3 to keep more cash in the company
Admitted shares 3,223,936
Enrico Bastianelli (CEO) 20,43 %
Other shareholders 5,93 %
Free float 22,78 %
Innovation Fund 14,09 %
Investsud 11,34 %
Luxembourg Développement Europe 2 11,34 %
Theodorus III 14,09 %
Source: Cofisem - Last Update: 18 Feb 2024
level2
0,248 1.000 1
0,255 1.002 1
0,3 463 1
0,352 1.600 1
0,4 160 2
0,48 1.990 1
0,498 40.000 1
0,61 189 1
0,68 200 1
0,696 200 1
Theravet (BE0974387194) Euronext Growth Paris et Bruxelles : 0.234
52w: 0.234 – 2.4
https://www.thera.vet/en/home
https://www.theravet-finances.com/images/202404_Theravet_Company_Presentation_Competition_Sport_Horses.pdf
their products:
https://bioceravet.com/en/shop-bone-surgery/
https://bioceravet.com/en/shop-osteosarcoma/
https://bioceravet.com/en/shop-equine/
A company with a lot of potential, 0 new shares since IPO but mkt cap from 31 million to 0.7 million euro.
Have reduced the workforce by 1/3 to keep more cash in the company
Admitted shares 3,223,936
Enrico Bastianelli (CEO) 20,43 %
Other shareholders 5,93 %
Free float 22,78 %
Innovation Fund 14,09 %
Investsud 11,34 %
Luxembourg Développement Europe 2 11,34 %
Theodorus III 14,09 %
Source: Cofisem - Last Update: 18 Feb 2024
level2
0,248 1.000 1
0,255 1.002 1
0,3 463 1
0,352 1.600 1
0,4 160 2
0,48 1.990 1
0,498 40.000 1
0,61 189 1
0,68 200 1
0,696 200 1
Theravet (BE0974387194) Euronext Growth Paris et Bruxelles : 0.246
52w: 0.24 – 2.4
https://www.thera.vet/en/home
https://www.theravet-finances.com/images/202404_Theravet_Company_Presentation_Competition_Sport_Horses.pdf
their products:
https://bioceravet.com/en/shop-bone-surgery/
https://bioceravet.com/en/shop-osteosarcoma/
https://bioceravet.com/en/shop-equine/
A company with a lot of potential, 0 new shares since IPO but mkt cap from 31 million to 0.8 million euro.
Have reduced the workforce by 1/3 to keep more cash in the company
Admitted shares 3,223,936
Enrico Bastianelli (CEO) 20,43 %
Other shareholders 5,93 %
Free float 22,78 %
Innovation Fund 14,09 %
Investsud 11,34 %
Luxembourg Développement Europe 2 11,34 %
Theodorus III 14,09 %
Source: Cofisem - Last Update: 18 Feb 2024
Level2:
0,244 25 1
0,249 1.355 1
0,25 500 1
0,258 1.905 1
0,26 189 1
0,28 750 1
0,29 1.200 2
0,32 2.000 2
0,352 1.600 1
0,388 5.260 1
Theravet (BE0974387194) Euronext Growth Paris et Bruxelles : 0.246
52w: 0.24 – 2.4
https://www.thera.vet/en/home
https://www.theravet-finances.com/images/202404_Theravet_Company_Presentation_Competition_Sport_Horses.pdf
their products:
https://bioceravet.com/en/shop-bone-surgery/
https://bioceravet.com/en/shop-osteosarcoma/
https://bioceravet.com/en/shop-equine/
A company with a lot of potential, 0 new shares since IPO but mkt cap from 31 million to 0.8 million euro.
Have reduced the workforce by 1/3 to keep more cash in the company
Admitted shares 3,223,936
Enrico Bastianelli (CEO) 20,43 %
Other shareholders 5,93 %
Free float 22,78 %
Innovation Fund 14,09 %
Investsud 11,34 %
Luxembourg Développement Europe 2 11,34 %
Theodorus III 14,09 %
Source: Cofisem - Last Update: 18 Feb 2024
Level2:
0,244 25 1
0,249 1.355 1
0,25 500 1
0,258 1.905 1
0,26 189 1
0,28 750 1
0,29 1.200 2
0,32 2.000 2
0,352 1.600 1
0,388 5.260 1
Theravet (BE0974387194) Euronext Growth Paris et Bruxelles : 0.269
52w: 0.24 – 2.4
https://www.thera.vet/en/home
https://www.theravet-finances.com/images/202404_Theravet_Company_Presentation_Competition_Sport_Horses.pdf
their products:
https://bioceravet.com/en/shop-bone-surgery/
https://bioceravet.com/en/shop-osteosarcoma/
https://bioceravet.com/en/shop-equine/
A company with a lot of potential, 0 new shares since IPO but mkt cap from 31 million to 0.8 million euro.
Have reduced the workforce by 1/3 to keep more cash in the company
Admitted shares 3,223,936
Enrico Bastianelli (CEO) 20,43 %
Other shareholders 5,93 %
Free float 22,78 %
Innovation Fund 14,09 %
Investsud 11,34 %
Luxembourg Développement Europe 2 11,34 %
Theodorus III 14,09 %
Source: Cofisem - Last Update: 18 Feb 2024
Level2:
0,269 22 1
0,27 1.000 2
0,289 387 1
0,29 1.300 3
0,31 700 1
0,32 1.000 1
0,352 1.600 1
0,388 5.260 1
0,397 10 2
0,4 160 2
Theravet (BE0974387194) Euronext Growth Paris et Bruxelles : 0.269
52w: 0.24 – 2.4
https://www.thera.vet/en/home
https://www.theravet-finances.com/images/202404_Theravet_Company_Presentation_Competition_Sport_Horses.pdf
their products:
https://bioceravet.com/en/shop-bone-surgery/
https://bioceravet.com/en/shop-osteosarcoma/
https://bioceravet.com/en/shop-equine/
A company with a lot of potential, 0 new shares since IPO but mkt cap from 31 million to 0.8 million euro.
Have reduced the workforce by 1/3 to keep more cash in the company
Admitted shares 3,223,936
Enrico Bastianelli (CEO) 20,43 %
Other shareholders 5,93 %
Free float 22,78 %
Innovation Fund 14,09 %
Investsud 11,34 %
Luxembourg Développement Europe 2 11,34 %
Theodorus III 14,09 %
Source: Cofisem - Last Update: 18 Feb 2024
Level2:
0,269 22 1
0,27 1.000 2
0,289 387 1
0,29 1.300 3
0,31 700 1
0,32 1.000 1
0,352 1.600 1
0,388 5.260 1
0,397 10 2
0,4 160 2
Theravet (BE0974387194) Euronext Growth Paris et Bruxelles : 0.278
52w: 0.278 – 2.4
https://www.thera.vet/en/home
https://www.theravet-finances.com/images/202404_Theravet_Company_Presentation_Competition_Sport_Horses.pdf
their products:
https://bioceravet.com/en/shop-bone-surgery/
https://bioceravet.com/en/shop-osteosarcoma/
https://bioceravet.com/en/shop-equine/
A company with a lot of potential, 0 new shares since IPO but mkt cap from 31 million to 0.9 million euro.
Admitted shares 3,223,936
Enrico Bastianelli (CEO) 20,43 %
Other shareholders 5,93 %
Free float 22,78 %
Innovation Fund 14,09 %
Investsud 11,34 %
Luxembourg Développement Europe 2 11,34 %
Theodorus III 14,09 %
Source: Cofisem - Last Update: 18 Feb 2024
Theravet (BE0974387194) Euronext Growth Paris et Bruxelles : 0.278
52w: 0.278 – 2.4
https://www.thera.vet/en/home
https://www.theravet-finances.com/images/202404_Theravet_Company_Presentation_Competition_Sport_Horses.pdf
their products:
https://bioceravet.com/en/shop-bone-surgery/
https://bioceravet.com/en/shop-osteosarcoma/
https://bioceravet.com/en/shop-equine/
A company with a lot of potential, 0 new shares since IPO but mkt cap from 31 million to 0.9 million euro.
Admitted shares 3,223,936
Enrico Bastianelli (CEO) 20,43 %
Other shareholders 5,93 %
Free float 22,78 %
Innovation Fund 14,09 %
Investsud 11,34 %
Luxembourg Développement Europe 2 11,34 %
Theodorus III 14,09 %
Source: Cofisem - Last Update: 18 Feb 2024
Theravet (BE0974387194) Euronext Growth Paris et Bruxelles
Time for a strong rebound:
Jul 16, 2024 0.3380 0.3540 0.2800 0.2810 0.2810 41,887
Jul 12, 2024 0.3870 0.3870 0.3650 0.3710 0.3710 11,879
Jul 11, 2024 0.3940 0.3940 0.3550 0.3800 0.3800 17,451
Jul 10, 2024 0.4390 0.4430 0.3760 0.3990 0.3990 10,413
Jul 09, 2024 0.4500 0.4510 0.4380 0.4390 0.4390 701
Jul 08, 2024 0.4550 0.4570 0.4500 0.4500 0.4500 2,079
Jul 05, 2024 0.4560 0.4590 0.4550 0.4550 0.4550 700
Jul 04, 2024 0.4610 0.4610 0.4600 0.4600 0.4600 555
Jul 03, 2024 0.4740 0.4740 0.4520 0.4650 0.4650 4,641
Jul 02, 2024 0.4610 0.4650 0.4500 0.4650 0.4650 1,530
Jul 01, 2024 0.4750 0.4750 0.4560 0.4730 0.4730 942
Jun 28, 2024 0.4750 0.4750 0.4600 0.4750 0.4750 769
Jun 27, 2024 0.4900 0.4950 0.4720 0.4800 0.4800 1,467
Jun 26, 2024 0.4920 0.4960 0.4500 0.4900 0.4900 25,477
Jun 25, 2024 0.5000 0.5000 0.4820 0.4960 0.4960 4,331
Jun 24, 2024 0.5000 0.5020 0.4980 0.4980 0.4980 788
Jun 21, 2024 0.5080 0.5080 0.5000 0.5080 0.5080 335
Jun 20, 2024 0.4820 0.5160 0.4820 0.5100 0.5100 5,919
Jun 19, 2024 0.5280 0.5280 0.5020 0.5280 0.5280 3,175
Jun 18, 2024 0.5200 0.5240 0.4820 0.5200 0.5200 6,510
Jun 17, 2024 0.5320 0.5320 0.4800 0.5200 0.5200 13,794
Jun 14, 2024 0.5640 0.5640 0.5320 0.5320 0.5320 1,482
Jun 13, 2024 0.5520 0.5680 0.5400 0.5640 0.5640 3,425
Jun 12, 2024 0.5760 0.5780 0.5480 0.5700 0.5700 4,081
Jun 11, 2024 0.5820 0.5820 0.5420 0.5760 0.5760 12,397
Jun 10, 2024 0.5820 0.5820 0.5820 0.5820 0.5820 22
Jun 07, 2024 0.5800 0.5820 0.5600 0.5820 0.5820 7,494
Jun 06, 2024 0.5800 0.5820 0.5300 0.5800 0.5800 8,335
Jun 05, 2024 0.5800 0.5800 0.5800 0.5800 0.5800 3,920
Jun 04, 2024 0.5800 0.5880 0.5600 0.5800 0.5800 5,377
Jun 03, 2024 0.5980 0.6060 0.5800 0.5800 0.5800 7,427
May 31, 2024 0.6100 0.6100 0.5700 0.5980 0.5980 4,671
May 30, 2024 0.6100 0.6100 0.5920 0.5960 0.5960 495
May 29, 2024 0.6100 0.6100 0.5800 0.6000 0.6000 742
May 28, 2024 0.6300 0.6300 0.6000 0.6220 0.6220 3,486
May 27, 2024 0.6480 0.6480 0.6000 0.6240 0.6240 3,802
May 24, 2024 0.6460 0.6540 0.5980 0.6380 0.6380 22,294
May 23, 2024 0.6560 0.6580 0.6000 0.6400 0.6400 2,946
May 22, 2024 0.6800 0.6800 0.6000 0.6560 0.6560 8,124
May 21, 2024 0.6400 0.6720 0.6280 0.6600 0.6600 6,538
May 20, 2024 0.6760 0.6860 0.6720 0.6740 0.6740 1,298
May 17, 2024 0.6820 0.6820 0.6760 0.6760 0.6760 253
May 16, 2024 0.6860 0.6860 0.6420 0.6820 0.6820 4,675
May 15, 2024 0.6840 0.6840 0.6600 0.6800 0.6800 1,265
May 14, 2024 0.6860 0.6860 0.6540 0.6840 0.6840 5,147
May 13, 2024 0.7100 0.7100 0.6800 0.6840 0.6840 1,969
May 10, 2024 0.7000 0.7080 0.7000 0.7060 0.7060 44
May 09, 2024 0.7000 0.7000 0.7000 0.7000 0.7000 534
May 08, 2024 0.6800 0.7000 0.6780 0.6980 0.6980 2,587
May 07, 2024 0.7000 0.7320 0.6400 0.6980 0.6980 18,725
May 06, 2024 0.6740 0.6960 0.6700 0.6920 0.6920 3,170
May 03, 2024 0.6840 0.6960 0.6680 0.6960 0.6960 1,622
May 02, 2024 0.6960 0.6960 0.6520 0.6960 0.6960 4,122
Apr 30, 2024 0.6700 0.7000 0.6660 0.6960 0.6960 6,416
Apr 29, 2024 0.7000 0.7000 0.6800 0.7000 0.7000 4,836
Apr 26, 2024 0.7800 0.7800 0.7100 0.7100 0.7100 8,021
Apr 25, 2024 0.7800 0.7800 0.7500 0.7780 0.7780 1,043
Apr 24, 2024 0.7500 0.7900 0.7500 0.7900 0.7900 11,791
Apr 23, 2024 0.7800 0.7880 0.7780 0.7780 0.7780 2,380
Apr 22, 2024 0.7900 0.7900 0.7440 0.7800 0.7800 2,256
Apr 19, 2024 0.7300 0.7800 0.7000 0.7800 0.7800 5,794
Apr 18, 2024 0.7640 0.7700 0.7000 0.7320 0.7320 10,253
Apr 17, 2024 0.7420 0.7800 0.7200 0.7800 0.7800 12,173
Apr 16, 2024 0.7800 0.8100 0.7140 0.7880 0.7880 19,952
Apr 15, 2024 0.8320 0.8320 0.7800 0.7800 0.7800 6,621
Apr 12, 2024 0.8400 0.8480 0.8300 0.8300 0.8300 2,148
Apr 11, 2024 0.8600 0.8600 0.8100 0.8400 0.8400 4,840
Apr 10, 2024 0.9200 0.9880 0.8600 0.8600 0.8600 71,490
Theravet (BE0974387194) Euronext Growth Paris et Bruxelles
Time for a strong rebound:
Jul 16, 2024 0.3380 0.3540 0.2800 0.2810 0.2810 41,887
Jul 12, 2024 0.3870 0.3870 0.3650 0.3710 0.3710 11,879
Jul 11, 2024 0.3940 0.3940 0.3550 0.3800 0.3800 17,451
Jul 10, 2024 0.4390 0.4430 0.3760 0.3990 0.3990 10,413
Jul 09, 2024 0.4500 0.4510 0.4380 0.4390 0.4390 701
Jul 08, 2024 0.4550 0.4570 0.4500 0.4500 0.4500 2,079
Jul 05, 2024 0.4560 0.4590 0.4550 0.4550 0.4550 700
Jul 04, 2024 0.4610 0.4610 0.4600 0.4600 0.4600 555
Jul 03, 2024 0.4740 0.4740 0.4520 0.4650 0.4650 4,641
Jul 02, 2024 0.4610 0.4650 0.4500 0.4650 0.4650 1,530
Jul 01, 2024 0.4750 0.4750 0.4560 0.4730 0.4730 942
Jun 28, 2024 0.4750 0.4750 0.4600 0.4750 0.4750 769
Jun 27, 2024 0.4900 0.4950 0.4720 0.4800 0.4800 1,467
Jun 26, 2024 0.4920 0.4960 0.4500 0.4900 0.4900 25,477
Jun 25, 2024 0.5000 0.5000 0.4820 0.4960 0.4960 4,331
Jun 24, 2024 0.5000 0.5020 0.4980 0.4980 0.4980 788
Jun 21, 2024 0.5080 0.5080 0.5000 0.5080 0.5080 335
Jun 20, 2024 0.4820 0.5160 0.4820 0.5100 0.5100 5,919
Jun 19, 2024 0.5280 0.5280 0.5020 0.5280 0.5280 3,175
Jun 18, 2024 0.5200 0.5240 0.4820 0.5200 0.5200 6,510
Jun 17, 2024 0.5320 0.5320 0.4800 0.5200 0.5200 13,794
Jun 14, 2024 0.5640 0.5640 0.5320 0.5320 0.5320 1,482
Jun 13, 2024 0.5520 0.5680 0.5400 0.5640 0.5640 3,425
Jun 12, 2024 0.5760 0.5780 0.5480 0.5700 0.5700 4,081
Jun 11, 2024 0.5820 0.5820 0.5420 0.5760 0.5760 12,397
Jun 10, 2024 0.5820 0.5820 0.5820 0.5820 0.5820 22
Jun 07, 2024 0.5800 0.5820 0.5600 0.5820 0.5820 7,494
Jun 06, 2024 0.5800 0.5820 0.5300 0.5800 0.5800 8,335
Jun 05, 2024 0.5800 0.5800 0.5800 0.5800 0.5800 3,920
Jun 04, 2024 0.5800 0.5880 0.5600 0.5800 0.5800 5,377
Jun 03, 2024 0.5980 0.6060 0.5800 0.5800 0.5800 7,427
May 31, 2024 0.6100 0.6100 0.5700 0.5980 0.5980 4,671
May 30, 2024 0.6100 0.6100 0.5920 0.5960 0.5960 495
May 29, 2024 0.6100 0.6100 0.5800 0.6000 0.6000 742
May 28, 2024 0.6300 0.6300 0.6000 0.6220 0.6220 3,486
May 27, 2024 0.6480 0.6480 0.6000 0.6240 0.6240 3,802
May 24, 2024 0.6460 0.6540 0.5980 0.6380 0.6380 22,294
May 23, 2024 0.6560 0.6580 0.6000 0.6400 0.6400 2,946
May 22, 2024 0.6800 0.6800 0.6000 0.6560 0.6560 8,124
May 21, 2024 0.6400 0.6720 0.6280 0.6600 0.6600 6,538
May 20, 2024 0.6760 0.6860 0.6720 0.6740 0.6740 1,298
May 17, 2024 0.6820 0.6820 0.6760 0.6760 0.6760 253
May 16, 2024 0.6860 0.6860 0.6420 0.6820 0.6820 4,675
May 15, 2024 0.6840 0.6840 0.6600 0.6800 0.6800 1,265
May 14, 2024 0.6860 0.6860 0.6540 0.6840 0.6840 5,147
May 13, 2024 0.7100 0.7100 0.6800 0.6840 0.6840 1,969
May 10, 2024 0.7000 0.7080 0.7000 0.7060 0.7060 44
May 09, 2024 0.7000 0.7000 0.7000 0.7000 0.7000 534
May 08, 2024 0.6800 0.7000 0.6780 0.6980 0.6980 2,587
May 07, 2024 0.7000 0.7320 0.6400 0.6980 0.6980 18,725
May 06, 2024 0.6740 0.6960 0.6700 0.6920 0.6920 3,170
May 03, 2024 0.6840 0.6960 0.6680 0.6960 0.6960 1,622
May 02, 2024 0.6960 0.6960 0.6520 0.6960 0.6960 4,122
Apr 30, 2024 0.6700 0.7000 0.6660 0.6960 0.6960 6,416
Apr 29, 2024 0.7000 0.7000 0.6800 0.7000 0.7000 4,836
Apr 26, 2024 0.7800 0.7800 0.7100 0.7100 0.7100 8,021
Apr 25, 2024 0.7800 0.7800 0.7500 0.7780 0.7780 1,043
Apr 24, 2024 0.7500 0.7900 0.7500 0.7900 0.7900 11,791
Apr 23, 2024 0.7800 0.7880 0.7780 0.7780 0.7780 2,380
Apr 22, 2024 0.7900 0.7900 0.7440 0.7800 0.7800 2,256
Apr 19, 2024 0.7300 0.7800 0.7000 0.7800 0.7800 5,794
Apr 18, 2024 0.7640 0.7700 0.7000 0.7320 0.7320 10,253
Apr 17, 2024 0.7420 0.7800 0.7200 0.7800 0.7800 12,173
Apr 16, 2024 0.7800 0.8100 0.7140 0.7880 0.7880 19,952
Apr 15, 2024 0.8320 0.8320 0.7800 0.7800 0.7800 6,621
Apr 12, 2024 0.8400 0.8480 0.8300 0.8300 0.8300 2,148
Apr 11, 2024 0.8600 0.8600 0.8100 0.8400 0.8400 4,840
Apr 10, 2024 0.9200 0.9880 0.8600 0.8600 0.8600 71,490
Great news:
Organovo Holdings, Inc. (ONVO) : 0.678
Pre-Market
$0.8789 + 0.2009 (29.63%)
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that Executive Chairman Keith Murphy presented on the company’s near and long-term outlook, operational plans, at the Jones Trading Healthcare Conference in Encinitas, CA. The webcast was recorded and can be viewed at https://wsw.com/webcast/jones/onvo/1848798.
“The promise of FXR314 is strong and I encourage investors to review our newest presentation,” said Keith Murphy, Executive Chairman. “As mergers and acquisitions continue to be strong in inflammatory bowel disease, highlighted by the Lilly acquisition of Morphic for $3.2B after strong Phase 2a results, we are encouraged by our progress and our near-term opportunity to show the value of FXR314 in IBD in our own Phase 2a trial. Completing the trial swiftly is important for our investors and for patients, as we expect to demonstrate activity of FXR314 that matches the strong results we’ve seen in a highly predictive preclinical animal model, as well as the strong data demonstrating the impact of FXR314 to relieve disease aspects in our 3d human models of ulcerative colitis and Crohn’s disease.”
About Organovo
Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company’s lead molecule, FXR314, is on the path for Phase 2 investigation in inflammatory bowel disease and has potential application in metabolic liver disease and oncology. The company has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. For more information visit Organovo's website at www.organovo.com.
Great news:
Organovo Holdings, Inc. (ONVO) : 0.678
Pre-Market
$0.8789 + 0.2009 (29.63%)
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that Executive Chairman Keith Murphy presented on the company’s near and long-term outlook, operational plans, at the Jones Trading Healthcare Conference in Encinitas, CA. The webcast was recorded and can be viewed at https://wsw.com/webcast/jones/onvo/1848798.
“The promise of FXR314 is strong and I encourage investors to review our newest presentation,” said Keith Murphy, Executive Chairman. “As mergers and acquisitions continue to be strong in inflammatory bowel disease, highlighted by the Lilly acquisition of Morphic for $3.2B after strong Phase 2a results, we are encouraged by our progress and our near-term opportunity to show the value of FXR314 in IBD in our own Phase 2a trial. Completing the trial swiftly is important for our investors and for patients, as we expect to demonstrate activity of FXR314 that matches the strong results we’ve seen in a highly predictive preclinical animal model, as well as the strong data demonstrating the impact of FXR314 to relieve disease aspects in our 3d human models of ulcerative colitis and Crohn’s disease.”
About Organovo
Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company’s lead molecule, FXR314, is on the path for Phase 2 investigation in inflammatory bowel disease and has potential application in metabolic liver disease and oncology. The company has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. For more information visit Organovo's website at www.organovo.com.
Theravet (BE0974387194) Euronext Growth Paris et Bruxelles : 0.306
https://www.thera.vet/en/home
https://www.theravet-finances.com/images/202404_Theravet_Company_Presentation_Competition_Sport_Horses.pdf
their products:
https://bioceravet.com/en/shop-bone-surgery/
https://bioceravet.com/en/shop-osteosarcoma/
https://bioceravet.com/en/shop-equine/
52W 0.306 – 2.40
A company with a lot of potential, 0 new shares since IPO but mkt cap from 31 million to 1 million euro.
Admitted shares 3,223,936
Enrico Bastianelli (CEO) 20,43 %
Other shareholders 5,93 %
Free float 22,78 %
Innovation Fund 14,09 %
Investsud 11,34 %
Luxembourg Développement Europe 2 11,34 %
Theodorus III 14,09 %
Source: Cofisem - Last Update: 18 Feb 2024
Theravet (BE0974387194) Euronext Growth Paris et Bruxelles : 0.306
https://www.thera.vet/en/home
https://www.theravet-finances.com/images/202404_Theravet_Company_Presentation_Competition_Sport_Horses.pdf
their products:
https://bioceravet.com/en/shop-bone-surgery/
https://bioceravet.com/en/shop-osteosarcoma/
https://bioceravet.com/en/shop-equine/
52W 0.306 – 2.40
A company with a lot of potential, 0 new shares since IPO but mkt cap from 31 million to 1 million euro.
Admitted shares 3,223,936
Enrico Bastianelli (CEO) 20,43 %
Other shareholders 5,93 %
Free float 22,78 %
Innovation Fund 14,09 %
Investsud 11,34 %
Luxembourg Développement Europe 2 11,34 %
Theodorus III 14,09 %
Source: Cofisem - Last Update: 18 Feb 2024
Mullen Automotive, Inc. (MULN): 2.04
52 Week Range 1.9850 - 153.0000
Shares Outstanding 16.03M
Float 10.24M
Book Value Per Share (mrq) 11.92
Time we see a strong rebound:
Jul 08, 2024 2.3500 2.3900 2.0400 2.0800 2.0800 10,261,600
Jul 01, 2024 2.4000 2.5000 2.2500 2.3000 2.3000 4,052,400
Jun 24, 2024 2.6700 2.8000 2.3600 2.4000 2.4000 5,693,200
Jun 17, 2024 2.6200 2.8200 2.5000 2.6800 2.6800 5,980,100
Jun 10, 2024 2.8000 2.9700 2.5800 2.6600 2.6600 9,917,600
Jun 03, 2024 4.4000 4.4100 2.8200 2.8600 2.8600 14,306,200
May 27, 2024 4.3700 4.7800 3.6100 4.5300 4.5300 8,885,700
May 20, 2024 5.0700 5.3300 3.9400 4.3600 4.3600 7,642,100
May 13, 2024 6.0500 7.4500 4.7400 4.8600 4.8600 20,598,800
May 06, 2024 4.6000 7.8500 4.3600 6.0900 6.0900 68,205,100
Vehicle order to Doering Fleet Management is valued at approximately $11.5 million with first vehicle deliveries in late 2024
BREA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- Mullen Automotive, Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an electric vehicle (“EV”) manufacturer, announces today its subsidiary, Bollinger Motors, has reached an agreement to sell 70 all-electric Class 4 Bollinger B4 commercial trucks to Doering Fleet Management (“Doering”), one of the nation’s premier fleet management companies. The vehicle order is valued at approximately $11.5 million with first vehicle deliveries in late 2024. The Bollinger B4 will be the first Class 4 medium duty, all-electric truck offered by Doering.
“Our agreement with Doering Fleet Management is another important step forward for Bollinger Motors,” said Jim Connelly, chief revenue officer of Bollinger Motors. “Doering is one of the top names in the fleet management world and we are honored to have the Bollinger B4 become an environmentally friendly fleet option for their customers across the country.”
Doering has built its reputation over three decades through outstanding customer service and by matching their customers with the right vehicles for their unique business needs. The Bollinger B4 will be the first medium duty, all-electric truck offered by Doering.
“The Bollinger B4 is an innovative, world-class electric truck with outstanding performance and capability, and Bollinger Motors shares our commitment to outstanding customer service,” said Adam Berger, president of Doering Fleet Management. “For our customers seeking a medium duty electric truck, the Bollinger B4 will be a great option to meet their needs. We look forward to bringing the B4 into our suite of offerings.”
The Bollinger B4 Chassis Cab is an all-new, battery electric Class 4 commercial truck designed from the ground up with extensive fleet and upfitter input. Bollinger's unique chassis design protects the 800-volt battery and components to offer unparalleled capability, flexibility, performance and serviceability in the commercial market. Bollinger Motors recently qualified for federal clean vehicle purchasing incentives under the Inflation Reduction Act, which provides $40,000 in refundable tax credits per truck.
Bollinger Motors has reached several milestones in recent months, including: receiving the Certificate of Conformity from the Environmental Protection Agency; an 80 vehicle sale to Momentum Groups; a 50 vehicle sale to EnviroCharge; a five vehicle sale with Spencer Manufacturing; the addition of Nacarato Truck Centers, Nuss Truck & Equipment, and LaFontaine Auto Group as dealers and service centers; Our Next Energy in Novi, Michigan, to supply battery packs; Roush Industries in Livonia, Michigan, to manage vehicle assembly operations; Syncron as its warranty administration partner; and Amerit Fleet Solutions as its mobile service provider.
About Doering Fleet Management
Doering Fleet Management is a national fleet management provider serving clients across the USA through offices nationwide. Doering has a unique value proposition focused on career professionals driving long-term relationships with clients. Doering does not seek to be the largest, but rather focuses on being the best fleet management provider clients choose. Doering operates TESlease® (Transportation, Electric, Sustainable), an EV fleet leasing business since 2015, and DreamLease, an exotic vehicle leasing division. Doering also has a robust government and municipal fleet management group based in Orlando, Florida.
To learn more about the company, visit www.DoeringFleetManagement.com
About Bollinger Motors
Founded in 2015 by Robert Bollinger, Bollinger Motors, Inc. is a U.S.-based company headquartered in Oak Park, Michigan. Bollinger Motors is developing all-electric commercial chassis cab trucks, Classes 4-6. In September of 2022, Bollinger Motors became a majority owned company of Mullen Automotive, Inc. (NASDAQ: MULN). Learn more at www.BollingerMotors.com and www.MullenUSA.com.
About Mullen
Mullen Automotive (NASDAQ: MULN) is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. Recently, CARB issued HVIP approval on the Mullen THREE, Class 3 EV truck, providing up to a $45,000 cash voucher at time of vehicle purchase. The Company has also recently expanded its commercial dealer network with the addition of Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group and Eco Auto, providing sales and service coverage in key Midwest, West Coast and Pacific Northwest and New England markets. The Company also recently announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles.
To learn more about the Company, visit www.MullenUSA.com.
Mullen Automotive, Inc. (MULN): 2.04
52 Week Range 1.9850 - 153.0000
Shares Outstanding 16.03M
Float 10.24M
Book Value Per Share (mrq) 11.92
Time we see a strong rebound:
Jul 08, 2024 2.3500 2.3900 2.0400 2.0800 2.0800 10,261,600
Jul 01, 2024 2.4000 2.5000 2.2500 2.3000 2.3000 4,052,400
Jun 24, 2024 2.6700 2.8000 2.3600 2.4000 2.4000 5,693,200
Jun 17, 2024 2.6200 2.8200 2.5000 2.6800 2.6800 5,980,100
Jun 10, 2024 2.8000 2.9700 2.5800 2.6600 2.6600 9,917,600
Jun 03, 2024 4.4000 4.4100 2.8200 2.8600 2.8600 14,306,200
May 27, 2024 4.3700 4.7800 3.6100 4.5300 4.5300 8,885,700
May 20, 2024 5.0700 5.3300 3.9400 4.3600 4.3600 7,642,100
May 13, 2024 6.0500 7.4500 4.7400 4.8600 4.8600 20,598,800
May 06, 2024 4.6000 7.8500 4.3600 6.0900 6.0900 68,205,100
Vehicle order to Doering Fleet Management is valued at approximately $11.5 million with first vehicle deliveries in late 2024
BREA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- Mullen Automotive, Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an electric vehicle (“EV”) manufacturer, announces today its subsidiary, Bollinger Motors, has reached an agreement to sell 70 all-electric Class 4 Bollinger B4 commercial trucks to Doering Fleet Management (“Doering”), one of the nation’s premier fleet management companies. The vehicle order is valued at approximately $11.5 million with first vehicle deliveries in late 2024. The Bollinger B4 will be the first Class 4 medium duty, all-electric truck offered by Doering.
“Our agreement with Doering Fleet Management is another important step forward for Bollinger Motors,” said Jim Connelly, chief revenue officer of Bollinger Motors. “Doering is one of the top names in the fleet management world and we are honored to have the Bollinger B4 become an environmentally friendly fleet option for their customers across the country.”
Doering has built its reputation over three decades through outstanding customer service and by matching their customers with the right vehicles for their unique business needs. The Bollinger B4 will be the first medium duty, all-electric truck offered by Doering.
“The Bollinger B4 is an innovative, world-class electric truck with outstanding performance and capability, and Bollinger Motors shares our commitment to outstanding customer service,” said Adam Berger, president of Doering Fleet Management. “For our customers seeking a medium duty electric truck, the Bollinger B4 will be a great option to meet their needs. We look forward to bringing the B4 into our suite of offerings.”
The Bollinger B4 Chassis Cab is an all-new, battery electric Class 4 commercial truck designed from the ground up with extensive fleet and upfitter input. Bollinger's unique chassis design protects the 800-volt battery and components to offer unparalleled capability, flexibility, performance and serviceability in the commercial market. Bollinger Motors recently qualified for federal clean vehicle purchasing incentives under the Inflation Reduction Act, which provides $40,000 in refundable tax credits per truck.
Bollinger Motors has reached several milestones in recent months, including: receiving the Certificate of Conformity from the Environmental Protection Agency; an 80 vehicle sale to Momentum Groups; a 50 vehicle sale to EnviroCharge; a five vehicle sale with Spencer Manufacturing; the addition of Nacarato Truck Centers, Nuss Truck & Equipment, and LaFontaine Auto Group as dealers and service centers; Our Next Energy in Novi, Michigan, to supply battery packs; Roush Industries in Livonia, Michigan, to manage vehicle assembly operations; Syncron as its warranty administration partner; and Amerit Fleet Solutions as its mobile service provider.
About Doering Fleet Management
Doering Fleet Management is a national fleet management provider serving clients across the USA through offices nationwide. Doering has a unique value proposition focused on career professionals driving long-term relationships with clients. Doering does not seek to be the largest, but rather focuses on being the best fleet management provider clients choose. Doering operates TESlease® (Transportation, Electric, Sustainable), an EV fleet leasing business since 2015, and DreamLease, an exotic vehicle leasing division. Doering also has a robust government and municipal fleet management group based in Orlando, Florida.
To learn more about the company, visit www.DoeringFleetManagement.com
About Bollinger Motors
Founded in 2015 by Robert Bollinger, Bollinger Motors, Inc. is a U.S.-based company headquartered in Oak Park, Michigan. Bollinger Motors is developing all-electric commercial chassis cab trucks, Classes 4-6. In September of 2022, Bollinger Motors became a majority owned company of Mullen Automotive, Inc. (NASDAQ: MULN). Learn more at www.BollingerMotors.com and www.MullenUSA.com.
About Mullen
Mullen Automotive (NASDAQ: MULN) is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. Recently, CARB issued HVIP approval on the Mullen THREE, Class 3 EV truck, providing up to a $45,000 cash voucher at time of vehicle purchase. The Company has also recently expanded its commercial dealer network with the addition of Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group and Eco Auto, providing sales and service coverage in key Midwest, West Coast and Pacific Northwest and New England markets. The Company also recently announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles.
To learn more about the Company, visit www.MullenUSA.com.
Organovo Holdings, Inc. (ONVO) : 0.67
52 Week Range 0.6500 - 2.0500
ONVO Increases Cash and Improves Prospects
Organovo Holdings (NASDAQ:ONVO) is a biotechnology company that is both a developer of 3D tissue technology that has the potential to change the way treatments are discovered and tested, as well as being a creator of new therapies using that technology.
The company released its annual report for 2023, fiscal year ended March 31, 2024, which showed the company continuing to make progress to both change the way medicines are created and tested, as well as creating it own therapies. As with all clinical stage companies, cash available for operations is one of the key measures that we look at. Having a measure of certainty regarding the ability of the company to continue to operate and make progress toward its goals is a key component of all such companies. Regarding Organovo, we were extremely pleased to see, due to events after the March 31, 2024 cutoff date such as a share issuance, the company had approximately $7.0 million on its balance sheet. This infusion of cash reinforces our belief that Organovo can attract investors and will be able to continue to advance towards its goal.
Giving us additional confidence, the company recently released Phase 2 results for one of the therapies being advanced by ONVO by the name of FXR 314. The trial was to determine the effectiveness of FXR314 in treating metabolic function-associated steatohepatitis (MASH), which is a condition affecting approximately 115 million people worldwide according to the Boehringer Institute, which is expected to increase by roughly 25% by 2050. MASH, briefly, is a condition that can develop when excess fat is stored in the liver and causes inflammation of the liver, which can lead to a variety of problems, including liver failure. The serious nature of this condition is part of the reason we are excited about results from the Phase 2 trial, which showed a significant reduction in liver fat content for trial participants, with a mean reduction of 23% for those with 3 mg doses of FXR314, compared to a 6.1% reduction seen in those participants with a placebo.
Additionally, the company found that FXR 314 was found to be safe and effective. CEO Keith Murphy noted that, “The key findings of this study are that the once daily oral FXR314 demonstrated statistically significant liver fat reduction and excellent tolerability.”
These results reinforce our belief that ONVO is pursuing a path for developing drugs that is more effective and efficient and should prove to produce more impactful treatments.
As mentioned above, the company is a developer of 3D technology as well as a creator of new therapies. It is this dual path and how the two paths can work together that continues to excite us about Organovo. Regarding the 3D technology, Organovo’s advances in the area include cell type-specific compartments, prevalent intercellular tight junctions, and the formation of microvascular structures. Management believes these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs across multiple therapeutic areas. The company’s technology, known as NovoGen Bioprinters, are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. The Company believes that the use of its bioprinting platform as well as complementary 3D technologies will allow it to develop an understanding of disease biology that leads to validated novel drug targets and therapeutics to those targets to treat disease. To this point, the company’s technology has been used to create a wide variety of tissues such as: healthy liver, NASH (nonalcoholic steatohepatitis) liver, kidney, intestine, skin, vascular, bone, skeletal muscle, eye, breast and pancreatic tumor.
There are two avenues that we believe the company can benefit from this technology. First, Organovo can use the technology internally to develop drugs that are able to be tailored more specifically to the targeted condition because the company can manipulate the 3D created tissues to reflect the disease as it would appear in actual human tissue. This also allows the company to move through the initial stages of research and testing in a more rapid and precise manner, which makes the process more efficient and cost effective and the treatments potentially more effective.
Additionally, many clinical stage companies have no revenue inflows to help offset the costs of developing much needed treatments. However, as already demonstrated, Organovo has the ability to license the company’s 3D technology to other companies to aid in their research process, leading to a revenue stream coming into Organovo as it continues to push to bring treatments to the market. According to company management, any deal achieved with a pharma company, Organovo intends to avoid “fee for services” revenue, which it believes provides limited benefit. Instead, the company will target deals with large, up-front payments, followed by milestone payments that the company believe could be in the hundreds of millions of dollars. These deals will involve the company working with the pharma partner to push novel drugs to the market. The partner company would own the rights to the drug, but Organovo would expect to earn milestone payments as a drug advances and royalties upon a drug’s commencement of commercial sales. These deals can be hard to predict the timing or probability of, but when achieved they have the potential to provide further validation of the company’s science and approach, as well as being a potential catalyst for investors.
Organovo Holdings, Inc. (ONVO) : 0.67
52 Week Range 0.6500 - 2.0500
ONVO Increases Cash and Improves Prospects
Organovo Holdings (NASDAQ:ONVO) is a biotechnology company that is both a developer of 3D tissue technology that has the potential to change the way treatments are discovered and tested, as well as being a creator of new therapies using that technology.
The company released its annual report for 2023, fiscal year ended March 31, 2024, which showed the company continuing to make progress to both change the way medicines are created and tested, as well as creating it own therapies. As with all clinical stage companies, cash available for operations is one of the key measures that we look at. Having a measure of certainty regarding the ability of the company to continue to operate and make progress toward its goals is a key component of all such companies. Regarding Organovo, we were extremely pleased to see, due to events after the March 31, 2024 cutoff date such as a share issuance, the company had approximately $7.0 million on its balance sheet. This infusion of cash reinforces our belief that Organovo can attract investors and will be able to continue to advance towards its goal.
Giving us additional confidence, the company recently released Phase 2 results for one of the therapies being advanced by ONVO by the name of FXR 314. The trial was to determine the effectiveness of FXR314 in treating metabolic function-associated steatohepatitis (MASH), which is a condition affecting approximately 115 million people worldwide according to the Boehringer Institute, which is expected to increase by roughly 25% by 2050. MASH, briefly, is a condition that can develop when excess fat is stored in the liver and causes inflammation of the liver, which can lead to a variety of problems, including liver failure. The serious nature of this condition is part of the reason we are excited about results from the Phase 2 trial, which showed a significant reduction in liver fat content for trial participants, with a mean reduction of 23% for those with 3 mg doses of FXR314, compared to a 6.1% reduction seen in those participants with a placebo.
Additionally, the company found that FXR 314 was found to be safe and effective. CEO Keith Murphy noted that, “The key findings of this study are that the once daily oral FXR314 demonstrated statistically significant liver fat reduction and excellent tolerability.”
These results reinforce our belief that ONVO is pursuing a path for developing drugs that is more effective and efficient and should prove to produce more impactful treatments.
As mentioned above, the company is a developer of 3D technology as well as a creator of new therapies. It is this dual path and how the two paths can work together that continues to excite us about Organovo. Regarding the 3D technology, Organovo’s advances in the area include cell type-specific compartments, prevalent intercellular tight junctions, and the formation of microvascular structures. Management believes these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs across multiple therapeutic areas. The company’s technology, known as NovoGen Bioprinters, are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. The Company believes that the use of its bioprinting platform as well as complementary 3D technologies will allow it to develop an understanding of disease biology that leads to validated novel drug targets and therapeutics to those targets to treat disease. To this point, the company’s technology has been used to create a wide variety of tissues such as: healthy liver, NASH (nonalcoholic steatohepatitis) liver, kidney, intestine, skin, vascular, bone, skeletal muscle, eye, breast and pancreatic tumor.
There are two avenues that we believe the company can benefit from this technology. First, Organovo can use the technology internally to develop drugs that are able to be tailored more specifically to the targeted condition because the company can manipulate the 3D created tissues to reflect the disease as it would appear in actual human tissue. This also allows the company to move through the initial stages of research and testing in a more rapid and precise manner, which makes the process more efficient and cost effective and the treatments potentially more effective.
Additionally, many clinical stage companies have no revenue inflows to help offset the costs of developing much needed treatments. However, as already demonstrated, Organovo has the ability to license the company’s 3D technology to other companies to aid in their research process, leading to a revenue stream coming into Organovo as it continues to push to bring treatments to the market. According to company management, any deal achieved with a pharma company, Organovo intends to avoid “fee for services” revenue, which it believes provides limited benefit. Instead, the company will target deals with large, up-front payments, followed by milestone payments that the company believe could be in the hundreds of millions of dollars. These deals will involve the company working with the pharma partner to push novel drugs to the market. The partner company would own the rights to the drug, but Organovo would expect to earn milestone payments as a drug advances and royalties upon a drug’s commencement of commercial sales. These deals can be hard to predict the timing or probability of, but when achieved they have the potential to provide further validation of the company’s science and approach, as well as being a potential catalyst for investors.